Number of patients | 15 |
Sex | All females |
Age (years) | Median 58 (30 - 73) |
subtype | Luminal: 7 HER2: 5 Triple negative:3 |
BSI (Bone Scan Index) | Median 3.028 (0.22 - 12.265) |
Duration from bone metastasis diagnosis onset until Sr-89 administration (months) | Median 23 (0 - 51) |
Zoledronate and denosumab | Zoledronate: 10 (66.7%) Denosumab: 4 (26.7%) No: 1 (6.6%) |
Hormonal agents | Yes: 9 (60%) No: 6 (40%) |
Chemotherapeutic agents | Yes: 8 (53.3%) No: 7 (46.7%) |